HORSHAM, PA — Myonex has appointed Chief Financial Officer Greg Lavin as its next chief executive officer, marking a leadership transition aimed at accelerating the company’s evolution into a fully integrated clinical trial supply and commercial packaging provider. Lavin will assume the role on January 1, 2026, succeeding James Lovett, who is retiring after steering the company through a period of significant growth.
Lavin, an industry veteran with experience across clinical research, preclinical services and healthcare data analysis, has served as Myonex’s CFO for more than six years. During that time, he worked alongside Lovett to reshape the company from a comparator sourcing specialist into a broader clinical supply solutions platform.
Executive Chairman Michael Cohen said Lavin played a central role in Myonex’s strategic transformation and is well-positioned to lead the next stage of expansion. He noted that Lavin’s understanding of client needs and his familiarity with the clinical research ecosystem will help build on the company’s current momentum.
Lavin previously served as CFO of QPS Holdings, a private equity–backed contract research organization, where he oversaw integration efforts following multiple global acquisitions. He also held senior financial roles at SDI, Inc. and SDI Health, LLC, both private equity–backed healthcare businesses.
Lovett, who joined Myonex in 2017 and became CEO in 2019, will remain on the board of directors. His tenure included the opening of a 65,000-square-foot global headquarters in Horsham, the launch of the CTRx program supporting prescription access and localized drug supply for clinical trials, and several strategic acquisitions in Germany, the United States and France that expanded the company’s packaging, distribution and bioservices capabilities.
Lavin said he is honored to follow Lovett and intends to continue investing in patient-centric and client-first solutions. He added that Myonex’s expanded global footprint and diversified service offerings position the company to meet rising demand across clinical development.
Cohen thanked Lovett for his leadership and emphasized that the company enters this transition from a position of strength, with plans to build on its portfolio and broaden support for sponsors navigating increasingly complex clinical trials.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.